Melanoma Therapeutics Landscape Canvassed in In-demand GBI Research Report Published at MarketPublishers.com
29 Jan 2015 • by Natalie Aster
LONDON – Melanoma has been traditionally deemed to be an extremely challenging condition to treat with pharmacotherapy. However, in the recent past, a deeper understanding of the heterogeneity and pathophysiology of the disease, and particularly its most popular form (90-95% of all melanomas) such as cutaneous melanoma (CM), has developed in great measure. As a result, a number of novel drug agents indicated for CM have been approved since 2011, including Sylatron (peginterferon alfa-2b), Opdivo (nivolumab), Tafinlar (dabrafenib), Keytruda (pembrolizumab), Yervoy (ipilimumab), Mekinist (trametinib), and Zelboraf (vemurafenib). With the emergence of these drugs, the treatment options for CM patients have greatly improved, leading to unparalleled market growth.
The growing melanoma treatment population and the ongoing uptake of newly approved drugs are among the key factors which are expected to boost the sector’s growth in the offing. There are currently several promising molecules in development stage, such as Amgen’s talimogene laherparepvec (T-VEC), Polynoma’s seviprotimut-L, and Roche and Genentech’s cobimetinib along with Zelboraf, which are in development for CM, and also AstraZeneca’s selumetinib which is in development for the treatment of ocular melanoma (OM). Globally, the melanoma therapeutics sector is anticipated to grow from USD 1.3 billion in 2013 to USD 3.6 billion by 2020, posting around 15.5% CAGR during the period.
In-demand report “Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth” elaborated by GBI Research covers the melanoma therapeutics marketplace. It examines today’s marketed product landscape comprising product profiles of the key drugs to treat melanoma alongside comparisons of efficacy and safety parameters of the different drugs. The study analyses the melanoma pipeline by development stage, molecule target, molecular type and novelty; includes a comparative analysis of late-stage pipeline products that are likely to come into the market in the future. An overview of melanoma clinical trials by duration, size, failure rates, and endpoints (primary and secondary) is provided. Furthermore, multiscenario forecasts to 2020 for the leading developed melanoma markets are provided, as well as a discussion of the strategic consolidations landscape in melanoma is available.
Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth
Published: September, 2014
Price: US$ 4,995.00
More in-demand studies by the publisher can be found at GBI Research page.